Determination of low molecular weight proteinuria and prevalence of Dent disease in patients with focal segmental glomerulosclerosis
| Main study | Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial |
|---|---|
| Contact name | Lada Beara-Lasic |
| Contact phone | 919-541-8979 |
| Contact email | Lada.Beara-Lasic@va.gov |
| PI name | John Lieske |
| Owner | Lada Beara Lasic |
| Institution | Mayo Clinic |